Athersys Inc (NQ: ATHX )
1.920 USD -0.090 (-4.48%) Official Closing Price Updated: 7:58 PM EST, Jan 15, 2021 Add to My Watchlist
Press releases about Athersys Inc
UTHealth in Houston and Athersys Announce Commencement of Patient Enrollment in a Phase 2 Trial Evaluating MultiStem® Cell Therapy in Trauma
December 21, 2020
UTHealth and Athersys announce patient enrollment in an innovative clinical study of MultiStem® cell therapy for the treatment of traumatic injuries
Athersys Announces Three Appointments to Board of Directors
November 16, 2020
Athersys announces three appointments to its board of directors, deepening board expertise to prepare for future growth and commercialization.
Athersys announces Q3 earnings and initiation of MultiStem® Phase 2 clinical trial in patients with trauma related inflammation and complications
Athersys to Host Third Quarter Financial Results Call
October 08, 2020
Athersys, Inc. (Nasdaq: ATHX) will release its third quarter 2020 financial results on Monday, November 9, 2020.
Thinking about buying stock in Athersys, Party City, AcelRx Pharmaceuticals, Southwest Airlines, or Carnival Corp?
September 23, 2020
FDA Grants RMAT Designation to MultiStem Cell Therapy for the Treatment of Acute Respiratory Distress Syndrome
September 23, 2020
MultiStem is the only cell therapy program for acute respiratory distress syndrome (ARDS) that has both Fast Track and RMAT designation from the FDA.
Athersys Reports Second Quarter 2020 Results
August 10, 2020
Athersys has made progress during Q2 in key clinical programs and infrastructure to support its planned transition to becoming a commercial company.
Athersys to Host Second Quarter Financial Results Call
July 20, 2020
Athersys, Inc. (Nasdaq: ATHX) will release its second quarter 2020 financial results on Monday, August 10, 2020.
Thinking about buying stock in SINTX Technologies, China Automotive Systems, Athersys Inc, Theratechnologies, or Biocept Inc?
June 22, 2020
Athersys Announces Upcoming Presentations at the International Society of Cell and Gene Therapy Virtual Conference
May 18, 2020
Athersys taking a leading role at the International Society of Cell ad Gene Therapy Conference and will discuss MultiStem and the ARDS clinical trial.
Athersys Reports First Quarter 2020 Results
May 07, 2020
Athersys Q1 Earnings reflects multiple achievements for the Company, including obtaining FDA authorization to initiate two additional clinical trials.
Athersys Announces Commencement of Patient Enrollment in the MACOVIA Study, a Pivotal Phase 2/3 Trial Evaluating MultiStem® Cell Therapy for COVID-19 Induced ARDS
May 05, 2020
The first patients have been enrolled in the Athersys COVID-19 induced ARDS clinical program using MultiStem cell therapy.
Athersys and University Hospitals Cleveland Medical Center Announce Activation of the First Clinical Site for the MACOVIA Study, a Pivotal Phase 2/3 Study Evaluating MultiStem® Cell Therapy for COVID-
May 01, 2020
The first clinical site is now open for the MACOVIA study, a pivotal Phase 2/3 study evaluating MultiStem® cell therapy for COVID-19 induced ARDS
Athersys to Present at the Bank of America Merrill Lynch Virtual Healthcare Conference on May 14
April 29, 2020
Athersys presentation scheduled for May 14, 2020 at 8:20 AM EDT. A live webcast will be available at https://tinyurl.com/y73g9zud
Athersys to Host First Quarter Financial Results Call
April 21, 2020
Athersys will release its first quarter 2020 financial results at approximately 4:00 PM Eastern Time on Thursday, May 7, 2020.
Athersys, Inc. (NASDAQ: ATHX) (Athersys) today announced the closing of its previously announced underwritten public offering of 25,587,500 shares of its common stock, par value $0.001 per share...
Athersys, Inc. (NASDAQ: ATHX) (Athersys) today announced the pricing of its previously announced underwritten public offering of its common stock, par value $0.001 per share (Common Stock), at a price...
Athersys Announces Proposed Public Offering of Common Stock
April 15, 2020
Athersys, Inc. (NASDAQ: ATHX) (Athersys) announced today that it intends to offer for sale $50 million of shares of its common stock, par value $0.001 per share (Common Stock), in an underwritten...
FDA Authorizes Initiation of a Phase 2 Trial Evaluating MultiStem® Cell Therapy in Trauma Patients
April 15, 2020
Phase 2 study of cell therapy in trauma expands Company’s clinical programs focused on critical care
FDA Authorizes Athersys to Initiate a Pivotal Clinical Trial Evaluating MultiStem® Cell Therapy in Patients With COVID-19 Induced Acute Respiratory Distress Syndrome
April 13, 2020
Company plans to initiate a Phase 2/3 pivotal study in patients with COVID-19 induced ARDS this quarter
Vaccine For COVID-19 Health Crises “Possible” By Summer After FDA Fast-Tracks Clinical Trials
April 01, 2020
Tags Featured News
Vaccine for COVID-19 Health Crises "Possible" by Summer After FDA Fast-Tracks Clinical Trials
April 01, 2020
HEALIOS K.K. Increases Investment in Athersys by Fully Exercising Warrant to Acquire Additional Shares
March 30, 2020
Maia Hansen appointed to help Athersys to establish and manage a sustainable supply chain to support commercial success.
Clinical trial results in ARDS supported designation by BARDA as a "Highly Relevant" program for COVID-19 and other pathogens.
NetworkNewsBreaks – Athersys Inc. (NASDAQ: ATHX) Featured in Dawson James Research Report
February 12, 2020
Athersys to Host Year-End 2019 Financial Results Call
February 10, 2020
Athersys Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 03, 2020
Athersys, Inc. (“Athersys” or the “Company”) (NASDAQ: ATHX) announced today that, as previously disclosed in its Form 8-K filed with the Securities and Exchange Commission on January 16, 2020, the...
Athersys Names Ivor Macleod Chief Financial Officer
January 15, 2020
Highly experienced pharmaceutical industry executive joins leadership team as Company begins planning for potential approval and commercialization of MultiStem®